Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Siqing Fu, Lisle Nabell, Alexander T. Pearson, Rom Leidner, Douglas Adkins, Marshall R. Posner, Jorge J. Nieva, Debra L. Richardson, Agustin Pimentel, Sanjay Goel, Stuart J. Wong, Alan Loh Ho, Ari Rosenberg, Matthew H. Taylor, Raghad Abdul-Karim, Corinne Iacobucci, Xiaoping Qing, Kia Katchar, Katia Schlienger, David G. Pfister
Institutions: The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, UAB Medicine, University of Chicago, Washington University in St. Louis, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Southern California, USC Norris Comprehensive Cancer Center, University of Oklahoma Health Sciences Center, University of Miami, Sylvester Comprehensive Cancer Center, Rutgers, The State University of New Jersey, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Henry Ford Hospital
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4281620365